Eyerising International is proud to introduce repeated low-level red-light therapy for slowing the progression of childhood myopia through the Eyerising Myopia Management Device. The device is non-invasive, available for children aged 3-16, and can be used either as monotherapy or in combination with all other myopia control treatments except low-dose atropine. 

Note: The Eyerising Myopia Management Device is available exclusively through eye care professionals, and the content on this page is for eye care professionals only.

Eyerising International

Org chart

Teams

Offices